| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 165.8 | 163.1 | 0.0 |
| Other income | 0.6 | 1.3 | 0.0 |
| Total income | 166.4 | 164.3 | 0.0 |
| Profit before exceptional items & tax | 12.5 | 11.4 | 0.0 |
| Profit before tax | 12.5 | 11.4 | 0.0 |
| Net profit | 8.2 | 8.4 | 0.0 |
| Operating margin | 7.5% | 6.9% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -2.40% |
|---|
BSE results filing, BSE: 544611. Figures extracted from the filing.
Mahamaya Lifesciences Ltd: key numbers
- Share price
- ₹174.80
- Market cap
- ₹409.1 Cr
- Revenue (annual)
- ₹329.3 Cr
- Net profit (annual)
- ₹16.72 Cr
- P/E (TTM)
- 24.5×Sector 36.8×
- Promoter holding
- 56.35%
- FII holding
- 4.77%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mahamaya Lifesciences Ltd
All →Mahamaya Lifesciences Promoter Buying
Promoter Prashant Krishnamurthy acquired 7,200 equity shares of Mahamaya Lifesciences Ltd through open market purchases on BSE.
- Promoter stake change
- +0.02%
Mahamaya Lifesciences Annual Report
Mahamaya Lifesciences Limited has filed its Annual Report for the financial year 2025-26. The document details the company's financial and operational performance.
Mahamaya Lifesciences Annual General Meeting
Mahamaya Lifesciences Limited has issued the notice for its Annual General Meeting scheduled on September 29, 2026. The agenda includes financial adoption and various director appointments.
Mahamaya Lifesciences Management Change
Mahamaya Lifesciences announced major leadership changes including the appointment of Mr. Amarendra Mohapatra as CFO and Mr. Kush Mishra as Company Secretary, effective November 2026 and August 2025 respectively.
Mahamaya Lifesciences Management Change
Mahamaya Lifesciences announced the resignation of Ms. Shilpi Bhardwaj from her position as Company Secretary, Compliance Officer, and Key Managerial Personnel.
Mahamaya Lifesciences Results Update
Mahamaya Lifesciences reported FY26 revenue of ₹328.87 Crore, representing 24.5% year-on-year growth. EBITDA rose 32.06%, reflecting strong operational performance and improved business momentum.
- Value
- ₹328.9 Cr